关键信息
-
基因名
CTAG1B
- 应用
-
别名
CTAG1B；CTAG；CTAG1；ESO1；Cancer/testis antigen 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P78358
-
表达区间
1-180aa
-
氨基酸序列
MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGA ARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPM EAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSIS SCLQQLSLLMWITQCFLPVFLAQPPSGQRR
-
分子量
48 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CTAG1B (Cancer/testis antigen 1B) is a gene located on chromosome X that encodes a protein primarily expressed in spermatogenic cells and various cancer tissues, making it a candidate for cancer immunotherapy. Its expression in tumors and limited presence in normal tissues highlights its potential as a biomarker for diagnosis and treatment strategies in malignancies, particularly in testicular cancer and melanoma. Research has shown that CTAG1B is involved in the regulation of immune responses, where it may elicit T-cell responses against tumors. The specificity of its expression in cancer cells provides a unique opportunity to develop targeted therapies, including vaccines and antibody-based treatments. Studies have also indicated that CTAG1B may be part of the larger category of cancer/testis antigens, which are of significant interest for their potential to differentiate between tumor and normal tissues, thus enabling a more personalized approach to cancer treatment. Investigating the recombinant form of CTAG1B can further elucidate its structure and function, paving the way for novel therapeutic interventions and enhancing the effectiveness of existing cancer vaccines. Overall, the research on CTAG1B recombinant protein represents a promising frontier in the development of immunotherapeutic strategies aimed at harnessing the immune system to combat cancer.
